Literature DB >> 34917879

Fully contrast-less EchoNavigator-guided left atrial appendage occlusion in a patient with severe chronic kidney disease.

Francesca Ciatti1, Miroslava Stolcova1, Carlo Di Mario1, Francesco Meucci1.   

Abstract

Entities:  

Year:  2021        PMID: 34917879      PMCID: PMC8669545          DOI: 10.1093/ehjcr/ytab436

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


× No keyword cloud information.
The EchoNavigator® (Philips Healthcare) is a recently introduced system able to integrate real-time information from transoesophageal echocardiography (TOE) and fluoroscopy in the same anatomical alignment, and its use has been associated with the reduction of radiation exposure and fluoroscopy time., The present case illustrates the advantages resulting from the use of intraprocedural guidance with the Echonavigator system (EN), in particular, the possibility to avoid any contrast dye. A 50-year-old hypertensive gentleman with a history of mitral and coronary artery disease, previous treated surgically, was referred for percutaneous left atrial appendage (LAA) occlusion because of permanent atrial fibrillation and a history of severe not-correctable gastrointestinal bleeding while on oral anticoagulant therapy. The patient also suffers from chronic kidney disease, and the estimated glomerular filtration rate was 40 mL/min/1.73 m2. Hence, pre-procedural planning with TOE was carried out showing a thrombus-free LAA with a landing zone of 21 mm. The LAA occlusion procedure was performed under general anaesthesia and TOE guidance, using fluoroscopic-echocardiographic fusion imaging from the EN software (Philips Healthcare, Amsterdam, Netherlands). At the beginning of the procedure, we placed fixed markers on the left circumflex artery and the tip of the Marshall band () that highlighted the LAA ostium and guided the subsequent catheter and device positioning in relation to relevant cardiac structures. EN provided significant advantages during the transseptal puncture (, Video 1) and guided the hardware and device orientation during the implantation (). A 25-mm Amplatzer Amulet (Abbott, Chicago, IL, USA) occluder device was chosen. Good stability of the implanted device (), no interference with the mitral valve apparatus (Video 2), and the correct final position were assessed by TOE (, Video 3). The patient was discharged home the day after and dual antiplatelet therapy was recommended for 1 month.
Figure 1

(A) Left circumflex and Marshall band markers placed at the beginning of the procedure. (B) Transseptal puncture is easily followed with the aid of echographic overlay that also helps with the positioning of the device inside the left atrial appendage (C). (D) The device is stable after a gentle pull-manoeuvre and a correct position is established with the Echonavigator system (E).

(A) Left circumflex and Marshall band markers placed at the beginning of the procedure. (B) Transseptal puncture is easily followed with the aid of echographic overlay that also helps with the positioning of the device inside the left atrial appendage (C). (D) The device is stable after a gentle pull-manoeuvre and a correct position is established with the Echonavigator system (E). Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance. Conflict of interest: None declared. Funding: None declared.
  2 in total

1.  Safety and feasibility of novel technology fusing echocardiography and fluoroscopy images during MitraClip interventions.

Authors:  Simon H Sündermann; Patric Biaggi; Jürg Grünenfelder; Michael Gessat; Christian Felix; Dominique Bettex; Volkmar Falk; Roberto Corti
Journal:  EuroIntervention       Date:  2014-02       Impact factor: 6.534

2.  Left Atrial Appendage Closure Guided by Integrated Echocardiography and Fluoroscopy Imaging Reduces Radiation Exposure.

Authors:  Christiane Jungen; Tobias Zeus; Jan Balzer; Christian Eickholt; Margot Petersen; Eva Kehmeier; Verena Veulemans; Malte Kelm; Stephan Willems; Christian Meyer
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.